• High-Purity Research Peptides
  • Fast Processing & Competitive Pricing

Larazotide Common Research Questions — Research Reference

By /

Larazotide (AT-1001) is a synthetically derived tight-junction-regulating peptide that has garnered significant attention in the scientific community for its observed modulatory effects on epithelial barrier function, particularly within intestinal-barrier research. Investigations into its mechanism of action and potential applications in various experimental models have led to numerous peer-reviewed publications indexed on PubMed, alongside several registered studies on ClinicalTrials.gov exploring its investigative utility in diverse research contexts. Researchers often seek a deeper understanding of its specific interactions with tight junction components, optimal experimental methodologies, and the scope of its utility across different preclinical models of barrier dysfunction.

This reference page compiles common research questions surrounding Larazotide, aiming to provide a comprehensive, research-use-only resource for scientists engaged in barrier function studies. By delving into the intricate biology of tight junctions, Larazotide’s proposed mechanisms, and the array of experimental paradigms available for its investigation, this document serves as a foundational guide for advancing preclinical research in this complex and critical area of physiology.

Understanding Tight Junctions and Barrier Integrity in Research

Tight junctions (TJs) are multiprotein complexes that form a critical seal between adjacent epithelial or endothelial cells, regulating paracellular permeability and maintaining cell polarity. These sophisticated structures are fundamental to the barrier function of various physiological systems, including the intestinal tract, blood-brain barrier, pulmonary epithelium, and renal tubules. In the context of research, understanding the intricate molecular architecture and dynamic regulation of TJs is paramount, as their dysfunction is implicated in the pathophysiology of numerous inflammatory, autoimmune, and metabolic conditions. The integrity of these barriers is not static; it is a highly regulated process influenced by a complex interplay of genetic, environmental, and microbial factors, making it a compelling area for preclinical investigation.

The molecular composition of tight junctions includes integral membrane proteins such as claudins, occludin, and junctional adhesion molecules (JAMs), which directly interact with proteins on adjacent cells to form the intercellular seal. These integral proteins are anchored to the actin cytoskeleton via a network of cytoplasmic adaptor proteins, including the zonula occludens (ZO) family (ZO-1, ZO-2, ZO-3). Research has demonstrated that the specific complement of claudin isoforms expressed in a given tissue largely determines the selectivity and permeability characteristics of the paracellular pathway, influencing the passage of ions, solutes, and macromolecules. Disruption of this intricate network, whether through direct protein cleavage, altered expression levels, or post-translational modifications, can lead to increased paracellular permeability, often referred to as “leaky barriers,” a state that is intensely studied in various disease models.

In gastrointestinal research, for instance, a compromised intestinal barrier is a hallmark feature observed in models of inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, as well as irritable bowel syndrome (IBS), celiac disease, and certain metabolic disorders. Here, increased intestinal permeability can allow the translocation of luminal antigens, toxins, and microbiota into the lamina propria, potentially triggering or exacerbating immune responses. Similarly, the blood-brain barrier (BBB), an extremely tight endothelial barrier, plays a crucial role in maintaining central nervous system (CNS) homeostasis. Research exploring BBB dysfunction has shown its involvement in neuroinflammation, neurodegenerative diseases, and neurological disorders, highlighting the broader implications of TJ integrity beyond the gastrointestinal tract. Consequently, compounds capable of modulating TJ function are of significant interest in preclinical research across diverse biological systems, seeking to elucidate their mechanisms and potential research applications.

The methodology employed to assess TJ integrity in research is diverse, ranging from electrophysiological measurements like transepithelial electrical resistance (TEER) in cell culture models to permeability assays using fluorescently labeled tracers in both *in vitro* and *in vivo* systems. Furthermore, molecular techniques such as immunohistochemistry, Western blotting, and quantitative PCR are routinely used to analyze the expression, localization, and phosphorylation status of key TJ proteins. Advanced imaging techniques, including electron microscopy, provide ultrastructural insights into junctional morphology. The consistent observation of compromised barrier function across a spectrum of preclinical disease models underscores the importance of TJs as a fundamental biological target for mechanistic research and the investigation of novel modulatory peptides.

Larazotide’s Proposed Mechanism of Action in Experimental Systems

Larazotide, also known by its research alias AT-1001, is a synthetic eight-amino acid peptide that has garnered significant attention in preclinical research due to its classification as a tight-junction-regulating peptide. Its proposed mechanism of action centers on modulating the paracellular pathway by influencing the integrity of tight junctions, primarily within epithelial barriers. Specifically, research suggests that Larazotide acts as a zonulin antagonist. Zonulin is a eukaryotic protein known to reversibly regulate intestinal tight junction permeability, acting to dismantle TJ complexes and increase paracellular permeability. By blocking the effects of zonulin, Larazotide is hypothesized to help maintain or restore the barrier function of epithelia under various experimental conditions. This direct interference with a key endogenous modulator of TJ integrity makes Larazotide a valuable tool for investigating the physiological consequences of altered barrier function.

The interaction of Larazotide with the zonulin pathway is believed to occur at a specific receptor on the surface of epithelial cells. Upon binding, Larazotide is thought to prevent zonulin from initiating its cascade of intracellular signaling events that typically lead to the rearrangement of actin filaments and the subsequent opening of tight junctions. This stabilization effect on the tight junction proteins, such as occludin, claudins, and ZO-1, could mitigate the increased permeability that is often observed in response to various stimuli, including inflammatory cytokines, toxins, or pathogens in research models. By preserving the integrity of the tight junction complex, Larazotide potentially limits the unrestricted passage of molecules through the paracellular space, thereby maintaining the selective barrier function essential for epithelial homeostasis. Researchers interested in the detailed molecular interactions can explore further at Larazotide’s Proposed Mechanism of Action.

Preclinical studies have utilized Larazotide to explore its effects across a range of experimental setups. In *in vitro* models, such as Caco-2 cell monolayers, the application of Larazotide has been shown to counteract the barrier-disrupting effects induced by various agents, often measured by an increase in transepithelial electrical resistance (TEER) or a reduction in the flux of paracellular tracers. These findings lend support to the hypothesis that Larazotide directly stabilizes tight junctions. Furthermore, in *ex vivo* Ussing chamber experiments using intestinal tissue, Larazotide has demonstrated an ability to reduce the permeability increase induced by inflammatory mediators. Such evidence from controlled research systems provides strong foundational support for its classification as a tight-junction-regulating peptide and highlights its utility in studying barrier function.

The precise signaling pathways downstream of Larazotide’s interaction with the zonulin receptor continue to be areas of active investigation in basic research. Understanding these intracellular events, including potential effects on protein kinase C or other kinase cascades implicated in TJ regulation, is crucial for a comprehensive elucidation of its mechanism. Researchers are also exploring how Larazotide might influence the expression levels or post-translational modifications of tight junction proteins themselves, beyond simply antagonizing zonulin’s immediate effects. This multifaceted approach to understanding Larazotide’s mechanism promises to uncover deeper insights into tight junction biology and its broader implications in maintaining physiological barriers in experimental systems.

Research Models for Investigating Larazotide’s Effects on Barrier Function

Investigating the effects of Larazotide on barrier function necessitates the use of a diverse array of research models, each offering unique advantages for elucidating its mechanisms and potential applications. These models span the spectrum from highly controlled *in vitro* cell culture systems to complex *in vivo* animal models, allowing researchers to incrementally build an understanding of Larazotide’s actions. The choice of model is often dictated by the specific research question, the desired level of biological complexity, and the feasibility of implementing certain assays.

In Vitro Cellular Models

Cell culture models are foundational for initial investigations into Larazotide’s direct effects on epithelial tight junctions. These models provide a controlled environment to study molecular interactions and dose-response relationships without the confounding factors present in whole organisms.

  • Caco-2 Cell Monolayers: Derived from human colon adenocarcinoma, Caco-2 cells spontaneously differentiate into polarized enterocyte-like cells forming tight junctions when cultured on semi-permeable membranes. They are widely used for permeability studies and assessing transepithelial electrical resistance (TEER), which serves as a quantitative measure of barrier integrity. Researchers can induce barrier dysfunction using various agents (e.g., pro-inflammatory cytokines, chemical stressors, microbial toxins) and then investigate Larazotide’s ability to attenuate or reverse these effects.
  • T84 Cell Monolayers: Another human colon carcinoma cell line, T84 cells, also form highly polarized monolayers with well-developed tight junctions, often exhibiting higher TEER values than Caco-2 cells, making them particularly sensitive for studying subtle changes in barrier function. Similar to Caco-2, they are invaluable for assessing the impact of Larazotide on paracellular permeability under controlled experimental conditions.
  • MDCK Cells (Madin-Darby Canine Kidney): These cells are commonly used to study epithelial transport and barrier formation. While not of intestinal origin, they offer a robust model for investigating general mechanisms of tight junction regulation and are often employed in early-stage peptide research.
  • Other Epithelial/Endothelial Cell Lines: Depending on the specific barrier of interest (e.g., blood-brain barrier, pulmonary barrier), researchers may utilize relevant cell lines such as bEnd.3 (brain endothelial cells), Calu-3 (pulmonary epithelial cells), or primary cell cultures to model the barrier *in vitro* and examine Larazotide’s effects.

Ex Vivo Tissue Models

*Ex vivo* models bridge the gap between *in vitro* cell cultures and *in vivo* animal studies by utilizing freshly excised tissues, preserving some of the tissue architecture and microenvironmental factors.

  • Ussing Chambers: This widely used technique employs sections of freshly isolated intestinal or colonic tissue (e.g., from rodents or biopsies) mounted in a chamber that separates the mucosal and serosal sides. It allows for direct measurement of ion transport, transepithelial electrical resistance, and the flux of radiolabeled or fluorescently tagged molecules across the intact tissue. Larazotide’s ability to modulate permeability in response to inflammatory stimuli can be directly assessed in this system, offering insights into its effects on a more physiologically relevant tissue.

In Vivo Animal Models

Animal models are essential for studying Larazotide’s systemic effects, pharmacokinetics, and pharmacodynamics in a complex physiological environment, where interactions with the immune system, microbiota, and multiple organ systems can be observed.

  • Rodent Models of Intestinal Inflammation:
    • Chemically Induced Colitis: Models such as dextran sulfate sodium (DSS)-induced colitis or trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice or rats are commonly employed to mimic aspects of human inflammatory bowel diseases. These models induce significant intestinal barrier dysfunction, which can be quantified by measuring serum levels of orally administered fluorescent dyes (e.g., FITC-dextran) or by histological assessment. Larazotide’s potential to preserve or restore barrier integrity in these models is a primary area of investigation.
    • Infection Models: Certain bacterial or viral infections can disrupt intestinal barrier function. Larazotide can be studied in models involving specific pathogens to assess its impact on infection-induced permeability changes.
  • Rodent Models of Metabolic Syndrome/Obesity: High-fat diet-induced obesity in rodents is often associated with alterations in gut microbiota and increased intestinal permeability. Larazotide can be investigated in these models to explore its role in mitigating diet-induced barrier dysfunction and its downstream consequences.
  • Models of Blood-Brain Barrier (BBB) Dysfunction: In conditions like experimental autoimmune encephalomyelitis (EAE) (a model for multiple sclerosis), stroke, or CNS infections, the BBB can become compromised. Researchers may explore Larazotide’s influence on BBB integrity using tracer extravasation assays (e.g., Evans blue, sodium fluorescein) or assessment of TJ protein expression in brain tissue.
  • Lung Injury Models: Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) models often involve pulmonary epithelial and endothelial barrier disruption. Larazotide’s effects on pulmonary permeability can be examined in rodent models of ventilator-induced lung injury or lipopolysaccharide (LPS)-induced ALI.

The judicious selection and combination of these research models are critical for generating robust and comprehensive data on Larazotide’s impact on barrier function. Each model contributes unique insights, from the precise molecular mechanisms observed in *in vitro* systems to the complex physiological responses observed in *in vivo* settings, collectively advancing the understanding of this tight-junction-regulating peptide.

Methodological Approaches to Studying Larazotide in Preclinical Research

The investigation of Larazotide’s effects on tight junction integrity and barrier function employs a multifaceted array of methodological approaches in preclinical research. These techniques are designed to quantify changes in permeability, visualize tight junction components, assess molecular expression, and understand the pharmacokinetics and pharmacodynamics of the peptide within experimental systems. A comprehensive research strategy typically involves combining several of these methods to provide a holistic picture of Larazotide’s biological activity.

Quantifying Barrier Permeability

Measuring permeability is a cornerstone of tight junction research. Various techniques are utilized, each providing different insights into the paracellular pathway.

Methodological Approach Principle of Measurement Typical Application Key Advantages
Transepithelial Electrical Resistance (TEER) Measures the electrical resistance across a cell monolayer or tissue, inversely proportional to paracellular ion flow. In vitro (Caco-2, T84 cells), Ex vivo (Ussing chamber). Non-destructive, real-time, quantitative, sensitive to subtle changes in tight junction integrity.
Paracellular Flux Assays Measures the passage of inert, non-metabolized tracer molecules (e.g., FITC-dextran, horseradish peroxidase) across a barrier. In vitro (cell monolayers), Ex vivo (Ussing chamber), In vivo (oral gavage & serum/urine detection). Direct quantification of macromolecular permeability, adaptable to various tracer sizes.
Lactulose/Mannitol Test Measures the urinary ratio of orally administered disaccharide lactulose (poorly absorbed) to monosaccharide mannitol (well absorbed) as an indicator of intestinal permeability. In vivo (rodent models). Physiologically relevant, non-invasive in research animals.
Biotinylation Assays Uses non-permeant biotin derivatives to label cell surface proteins, followed by pull-down and Western blot, to assess tight junction protein localization at the membrane. In vitro (cell monolayers), Ex vivo (tissue fragments). Provides insights into protein distribution and junctional integrity at the molecular level.

Molecular and Imaging Techniques

Beyond permeability measurements, understanding the molecular changes in tight junction proteins themselves is critical.

  • Immunofluorescence and Confocal Microscopy: Used to visualize the localization, distribution, and integrity of tight junction proteins (e.g., ZO-1, occludin, claudins) within cell monolayers or tissue sections. Changes in staining patterns (e.g., discontinuous or cytoplasmic localization instead of continuous linear staining at cell borders) indicate barrier disruption, while Larazotide’s effects can be assessed by observing restoration of normal patterns.
  • Western Blotting and Quantitative PCR (qPCR): These techniques are employed to quantify the expression levels of tight junction proteins at the protein (Western blot) and mRNA (qPCR) level. Larazotide’s influence on the transcriptional or translational regulation of these key structural components can thus be investigated. Phosphorylation status of TJ proteins, which can regulate their function, can also be assessed via Western blotting with phosphospecific antibodies.
  • Electron Microscopy (Transmission Electron Microscopy – TEM): Provides ultrastructural resolution to directly visualize the tight junction complexes at the nanometer scale. TEM can reveal subtle changes in junctional morphology, such as widening of the paracellular space or alterations in the number and integrity of tight junction strands, offering direct evidence of Larazotide’s impact on junctional architecture.
  • Co-Immunoprecipitation: Used to study protein-protein interactions within the tight junction complex, revealing how Larazotide might influence the assembly or stability of these multi-protein structures by altering the binding of specific components.

Pharmacokinetic and Pharmacodynamic Studies

To fully characterize Larazotide in preclinical research, it is essential to understand its behavior within biological systems.

  • Pharmacokinetic (PK) Studies: These studies determine the absorption, distribution, metabolism, and excretion (ADME) profile of Larazotide in animal models. Techniques such as liquid chromatography-mass spectrometry (LC-MS) are used to quantify peptide concentrations in plasma, tissues, and excreta following various routes of administration (e.g., oral, intravenous). PK data helps inform dosing strategies and understand systemic exposure.
  • Pharmacodynamic (PD) Studies: PD studies investigate the biological effects of Larazotide and the relationship between its concentration and its observed effects on tight junction function. This can involve correlating plasma or tissue concentrations of Larazotide with changes in TEER, paracellular flux, or TJ protein expression in target tissues in a dose-dependent manner. This research provides crucial insights into how much peptide is needed to elicit a desired research effect.

By integrating these diverse methodological approaches, researchers can rigorously investigate Larazotide’s proposed mechanism of action, evaluate its efficacy in various barrier dysfunction models, and generate comprehensive data to guide future preclinical studies. The precision and reproducibility of these methods are paramount for drawing robust conclusions in the dynamic field of tight junction research.

Larazotide in Research Beyond Intestinal Barrier Studies

While Larazotide (AT-1001) is most recognized for its investigation in intestinal barrier research, its role as a tight-junction-regulating peptide suggests broader applicability in preclinical studies involving other epithelial and endothelial barriers throughout the body. The fundamental mechanism of modulating tight junction integrity has implications for a variety of physiological systems where barrier dysfunction contributes to pathology. Researchers are increasingly exploring Larazotide’s potential impact in areas beyond the gut, pushing the boundaries of its investigative utility.

Blood-Brain Barrier (BBB) Research

The blood-brain barrier is a highly selective semipermeable barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS). It is formed by specialized endothelial cells connected by exceptionally tight junctions, which meticulously regulate the passage of substances into the brain. Dysfunction of the BBB is implicated in numerous neurological disorders, including neuroinflammation, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and post-stroke complications. Research is exploring whether Larazotide, by stabilizing tight junctions, could help maintain or restore BBB integrity in various experimental models of CNS pathology. This could potentially reduce the infiltration of inflammatory cells or harmful molecules into the brain parenchyma, thereby modulating neuroinflammatory responses or neurodegeneration in research contexts.

Pulmonary Barrier Research

The pulmonary epithelium forms another critical barrier, protecting the delicate lung tissue from environmental insults and pathogens. Tight junctions between alveolar and bronchial epithelial cells regulate the movement of fluids and solutes, essential for gas exchange and maintaining lung homeostasis. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by increased pulmonary vascular and epithelial permeability, leading to alveolar edema and impaired gas exchange. Preclinical studies are investigating Larazotide’s ability to attenuate barrier dysfunction in models of ALI/ARDS, potentially by preserving the integrity of alveolar epithelial tight junctions. This research aims to understand if Larazotide could help mitigate inflammatory responses and reduce fluid accumulation in the lungs under experimental conditions.

Renal and Urogenital Barrier Research

In the kidneys, tight junctions are crucial for maintaining the selective permeability of the renal tubules and glomeruli, essential for filtration and reabsorption processes. Dysfunction of these barriers can contribute to proteinurea and other forms of renal injury. Research into Larazotide’s effects on renal tight junctions could explore its utility in models of kidney disease where barrier compromise is a feature. Similarly, the urogenital tract possesses epithelial barriers that are vital for protection against infection and maintaining tissue integrity. Investigating Larazotide in models of urogenital inflammation or infection could reveal insights into its broader barrier-protective effects.

Dermatological and Ocular Research

The skin’s epidermis forms a robust physical barrier, and tight junctions are present in the stratum granulosum, contributing to its barrier function. In conditions involving compromised skin barrier (e.g., atopic dermatitis, psoriasis), increased permeability can allow allergen penetration and exacerbate inflammation. While less explored, Larazotide’s impact on dermal tight junctions could be an avenue for future research. Likewise, the ocular surface and blood-retinal barrier possess tight junctions critical for maintaining ocular health. Exploring Larazotide’s influence on these barriers in models of ocular inflammation or dry eye could open new research directions. These explorations highlight Larazotide’s potential as a versatile tool for probing tight junction biology across diverse physiological systems, extending its investigative scope far beyond its initial focus on the intestinal barrier.

Challenges and Considerations in Larazotide Research Methodologies

Researching a tight-junction-regulating peptide like Larazotide (AT-1001) presents a unique set of challenges and considerations that researchers must meticulously address to ensure the robustness, reproducibility, and interpretability of their findings. These challenges span from the intrinsic properties of peptide compounds to the complexities of modeling biological barriers *in vitro* and *in vivo*.

Peptide Stability and Delivery

  • Chemical and Enzymatic Degradation: Peptides are inherently susceptible to degradation by prote

    Frequently Asked Questions

    What is Larazotide’s (AT-1001) primary classification and proposed mechanism of action in research?

    Larazotide (AT-1001) is classified as a tight-junction-regulating peptide. Its proposed mechanism of action in research involves modulating the paracellular pathway by influencing the integrity and function of tight junctions between epithelial cells. This modulation is hypothesized to occur through interactions with specific components of the tight junction complex, thereby affecting barrier permeability in various experimental models, particularly those related to intestinal-barrier research.

    How can researchers access existing literature on Larazotide (AT-1001)?

    Researchers can access existing literature on Larazotide (AT-1001) through scientific databases such as PubMed. As a compound with numerous indexed publications, a simple search using “Larazotide” or “AT-1001” will yield a substantial body of peer-reviewed research articles detailing its preclinical investigations across various experimental settings and models.

    Are there registered clinical studies involving Larazotide (AT-1001) that researchers can review for contextual information?

    Yes, there are several registered studies involving Larazotide (AT-1001) that researchers can review for contextual information. These studies, primarily focusing on its investigative utility and observed effects in human research cohorts, are registered on platforms such as ClinicalTrials.gov. Accessing these entries can provide insights into the design, objectives, and parameters of human-focused investigations, which can inform the development of novel preclinical research hypotheses and models.

    What are common *in vitro* models used to study Larazotide’s (AT-1001) effects on barrier function?

    Common *in vitro* models used to study Larazotide’s (AT-1001) effects on barrier function include various epithelial cell lines, such as Caco-2, T84, and MDCK cells. These models, grown as monolayers on permeable supports, allow researchers to assess parameters like transepithelial electrical resistance (TEER) and paracellular flux of inert markers to quantify barrier integrity modulation in response to Larazotide treatment under controlled experimental conditions.

    What are common *in vivo* models used to investigate Larazotide’s (AT-1001) impact on intestinal barrier function?

    Common *in vivo* models for investigating Larazotide’s (AT-1001) impact on intestinal barrier function often involve rodent models of induced barrier dysfunction. These can include chemically induced colitis models (e.g., DSS or TNBS colitis), models of diet-induced intestinal permeability, or stress-induced barrier disruption models. Researchers typically assess markers of gut permeability (e.g., circulating FITC-dextran), inflammatory markers, and histological changes to evaluate Larazotide’s effects.

    Can Larazotide (AT-1001) be studied for its effects on tight junctions in non-intestinal barriers?

    Yes, Larazotide (AT-1001) can theoretically be studied for its effects on tight junctions in non-intestinal barriers. Given that tight junctions are fundamental components of many epithelial and endothelial barriers throughout the body (e.g., blood-brain barrier, respiratory epithelium, renal tubules), researchers could explore its modulatory potential in *in vitro* models derived from these tissues or in specific *in vivo* models of non-intestinal barrier dysfunction, provided appropriate research hypotheses are formulated.

    What are the primary experimental techniques for assessing tight junction integrity in Larazotide (AT-1001) research?

    The primary experimental techniques for assessing tight junction integrity in Larazotide (AT-1001) research include measuring transepithelial electrical resistance (TEER) in cell monolayers, quantifying the paracellular flux of inert macromolecular tracers (e.g., FITC-dextran, HRP), and analyzing the expression and localization of key tight junction proteins (e.g., occludin, claudins, ZO proteins) via Western blot, immunofluorescence, or immunohistochemistry. Electron microscopy can also provide ultrastructural details of tight junction morphology.

    How should researchers consider dosage and administration of Larazotide (AT-1001) in preclinical studies?

    Researchers should carefully consider the dosage and administration of Larazotide (AT-1001) in preclinical studies based on findings from existing literature, the specific research question, and the chosen experimental model. Optimal concentrations for *in vitro* studies and effective doses for *in vivo* models can vary widely depending on the cell line, animal species, route of administration, and the specific condition being investigated. Dose-response studies are crucial in establishing appropriate experimental parameters.

    Scientific References

    All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.

Scroll to Top